Peripheral Blood Stem Cell Transplantation for Chronic Myelogenous Leukemia

"Children as young as one year old and adults up to 75 years of age may be eligible for this clinical trial, based on the inclusion criteria. There are 1702 other studies being conducted for patients under 18 and 6172 trials available for seniors."

"This study is not admitting new patients at the moment. However, if you are seeking other studies, there are 6568 trials actively recruiting participants with thalassemia and 928 trials for Peripheral Blood Stem Cell Transplantation that may have open enrollment."

"This trial is not presently seeking participants anymore. The study was originally posted on 12/7/2017 and was most recently updated on 9/14/2022. If you are exploring for other studies, there are currently 6568 trials actively enrolling participants with thalassemia and 928 studies for Peripheral Blood Stem Cell Transplantation actively admitting participants."

"This treatment, while still in Phase 2 trials, has shown some promise in terms of safety. However, as it is still in the early stages of testing, there is no data yet supporting its efficacy."

"There are 928 clinical studies related to Peripheral Blood Stem Cell Transplantation currently underway. Of those, 165 are in Phase 3. The majority of trials for this treatment are based in Philadelphia, Pennsylvania; however, there are 28613 locations running trials for this treatment worldwide."

"While Peripheral Blood Stem Cell Transplantation is most often used to treat multiple sclerosis, it can also be an effective intervention for mixed-cell type lymphoma, leukemia, myelocytic, acute, and retinoblastoma."

"Up to 31 individuals aged 1 year or older who currently have thalassemia are eligible for this trial. Along with meeting the age criteria, patients must also have a left ventricular ejection fraction > 40%, a Karnofsky (adult) or Lansky (for =< 16 years) performance status >= 60%. Additionally, the recipient should not have any HLA antibodies to potential donors. If the patient does have HLA antibodies, an alternative donor is preferred; though if there are no suitable alternative donors, the anti-HLAt antibodies can be depleted per transplant service guidelines. Any disease that is considered transplant eligible per TCT"